Neratinib is indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab based therapy. Neratinib Maleate was developed by Wyeth John And Brother Ltd..
The API has now reached off-patent status, after being launched in 2017.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Neratinib Maleate and many others, contact info@pharmacheminvestor.com